Oral Session 2-9A MM: Global clinical trials

[OS2-9A-4] Efficacy and safety of DARA-VMP vs VMP by baseline renal function in non-transplant NDMM (ALCYONE)

Kenshi Suzuki¹, Michele Cavo², Meletios A. Dimopoulos³, Jesus San-Miguel⁴, Andrzej Jakubowiak⁵, Sung-Soo Yoon⁶, Mark Cook⁷, Mario Boccadoro⁸, P. Joy Ho⁹, Ludek Pour¹⁰, Stefan Knop¹¹, Chantal Doyen¹², Andre Crepaldi¹³, Tamas Masszi¹⁴, Joan Blade¹⁵, Jianping Wang¹⁶, Susan Wroblewski¹⁷, William Deraedt¹⁸, Ming Qi¹⁷, Maria-Victoria Mateos¹⁹ (1.Japanese Red Cross Medical Center, Department of Hematology, Tokyo, Japan, 2.Seragnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italian Republic, 3.National and Kapodistrian University of Athens, Athens, Hellenic Republic, 4.Clinica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain, 5.University of Chicago Medical Center, Chicago, United States of America, 6.Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, 7.University Hospitals Birmingham NHS Trust, Birmingham, United Kingdom of Great Britain and Northern Ireland, 8.Myeloma Unit, Division of Hematology, University of Torino, Torino, Italian Republic, 9.Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia, 10.University Hospital Brno, Brno, Czech Republic, 11.Wuerzburg University Medical Center, Wuerzburg, Federal Republic of Germany, 12.Universite catholique de Louvain (UcL) CHU UCL Namur, Yvoir, Kingdom of Belgium, 13.Clinica de Tratamento E, Cuiaba, Federative Republic of Brazil, 14.Department of Haematology and Stem Cell Transplantation, St Laszlo Hospital, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Republic of Hungary, 15.Servei d'Hematologia, Hospital Clinic de Barcelona, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain, 16.Janssen Research & Development, Raritan, United States of America, 17.Janssen Research & Development, Spring House, United States of America, 18.Janssen Research & Development, Beerse, Kingdom of Belgium, 19.University Hospital of Salamanca/IBSAL, Salamanca, Spain)